Terms: = Lung cancer AND MSI2, ENSG00000153944, 124540
13 results:
1.
Liu M; Du M; Yu J; Qian Z; Gao Y; Pan W; Zhao X; Wang M; Li H; Zheng J; Huang Q; Wang LM; Xiao H
Oncoimmunology; 2022; 11(1):2016158. PubMed ID: 35003895
[TBL] [Abstract] [Full Text] [Related]
2. MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.
Yiming R; Takeuchi Y; Nishimura T; Li M; Wang Y; Meguro-Horike M; Kohno T; Horike SI; Nakata A; Gotoh N
Cancer Sci; 2021 Sep; 112(9):3810-3821. PubMed ID: 34145929
[TBL] [Abstract] [Full Text] [Related]
3. Splicing reprogramming of TRAIL/DISC-components sensitizes lung cancer cells to TRAIL-mediated apoptosis.
Voss OH; Arango D; Tossey JC; Villalona Calero MA; Doseff AI
Cell Death Dis; 2021 Mar; 12(4):287. PubMed ID: 33731677
[TBL] [Abstract] [Full Text] [Related]
4. Myofibroblast-Specific msi2 Knockout Inhibits HCC Progression in a Mouse Model.
Qu C; He L; Yao N; Li J; Jiang Y; Li B; Peng S; Hu K; Chen D; Chen G; Huang W; Cao M; Fan J; Yuan Y; Ye W; Hong J
Hepatology; 2021 Jul; 74(1):458-473. PubMed ID: 33609283
[TBL] [Abstract] [Full Text] [Related]
5. Knockdown of msi2 inhibits metastasis by interacting with caveolin-1 and inhibiting its ubiquitylation in human NF1-MPNST cells.
Yang K; Du J; Shi D; Ji F; Ji Y; Pan J; Lv F; Zhang Y; Zhang J
Cell Death Dis; 2020 Jun; 11(6):489. PubMed ID: 32606289
[TBL] [Abstract] [Full Text] [Related]
6. Suppression of Musashi‑2 by the small compound largazole exerts inhibitory effects on malignant cells.
Wang M; Sun XY; Zhou YC; Zhang KJ; Lu YZ; Liu J; Huang YC; Wang GZ; Jiang S; Zhou GB
Int J Oncol; 2020 May; 56(5):1274-1283. PubMed ID: 32319553
[TBL] [Abstract] [Full Text] [Related]
7. ETV4 promotes proliferation and invasion of lung adenocarcinoma by transcriptionally upregulating msi2.
Cheng T; Zhang Z; Cheng Y; Zhang J; Tang J; Tan Z; Liang Z; Chen T; Liu Z; Li J; Zhao J; Zhou R
Biochem Biophys Res Commun; 2019 Aug; 516(1):278-284. PubMed ID: 31253395
[TBL] [Abstract] [Full Text] [Related]
8. Immunohistochemical and genetic characteristics of lung cancer mimicking organizing pneumonia.
Ichikawa T; Saruwatari K; Mimaki S; Sugano M; Aokage K; Kojima M; Hishida T; Fujii S; Yoshida J; Kuwata T; Ochiai A; Suzuki K; Tsuboi M; Goto K; Tsuchihara K; Ishii G
Lung Cancer; 2017 Nov; 113():134-139. PubMed ID: 29110840
[TBL] [Abstract] [Full Text] [Related]
9. Stem Cells, cancer, and MUSASHI in Blood and Guts.
Kharas MG; Lengner CJ
Trends Cancer; 2017 May; 3(5):347-356. PubMed ID: 28718412
[TBL] [Abstract] [Full Text] [Related]
10. Musashi RNA-Binding Proteins as cancer Drivers and Novel Therapeutic Targets.
Kudinov AE; Karanicolas J; Golemis EA; Boumber Y
Clin Cancer Res; 2017 May; 23(9):2143-2153. PubMed ID: 28143872
[TBL] [Abstract] [Full Text] [Related]
11. Musashi-2 (msi2) supports TGF-β signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis.
Kudinov AE; Deneka A; Nikonova AS; Beck TN; Ahn YH; Liu X; Martinez CF; Schultz FA; Reynolds S; Yang DH; Cai KQ; Yaghmour KM; Baker KA; Egleston BL; Nicolas E; Chikwem A; Andrianov G; Singh S; Borghaei H; Serebriiskii IG; Gibbons DL; Kurie JM; Golemis EA; Boumber Y
Proc Natl Acad Sci U S A; 2016 Jun; 113(25):6955-60. PubMed ID: 27274057
[TBL] [Abstract] [Full Text] [Related]
12. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.
Owonikoko TK; Zhang G; Deng X; Rossi MR; Switchenko JM; Doho GH; Chen Z; Kim S; Strychor S; Christner SM; Beumer J; Li C; Yue P; Chen A; Sica GL; Ramalingam SS; Kowalski J; Khuri FR; Sun SY
Cancer Med; 2014 Dec; 3(6):1579-94. PubMed ID: 25124282
[TBL] [Abstract] [Full Text] [Related]
13. Expression of seven stem-cell-associated markers in human airway biopsy specimens obtained via fiberoptic bronchoscopy.
Li L; Yu H; Wang X; Zeng J; Li D; Lu J; Wang C; Wang J; Wei J; Jiang M; Mo B
J Exp Clin Cancer Res; 2013 May; 32(1):28. PubMed ID: 23683495
[TBL] [Abstract] [Full Text] [Related]
